Meet Our Management Team

Dr. Talton is a co-founder, President, and CEO at Nanotherapeutics. Prior to founding Nanotherapeutics, Dr. Talton was the President and CEO of D&E Management Systems, a leading service organization in Florida, from 1993 to 1994. Dr. Talton is a co-inventor of Nanotherapeutics' technologies and has several authored peer-reviewed publications and book chapters involved in drug delivery systems, with a primary focus in drug analysis and controlled release formulations, pharmacokinetics, and pulmonary drug delivery. Dr. Talton received his B.S. and M.S. in Materials Science and Engineering and his Ph.D. in Pharmaceutical Sciences from the University of Florida.

Bärbel Eppler joined Nanotherapeutics in April 2001 as Director of the Bioanalytical Department and recently became the VP of Preclinical Development and QA. Prior to joining Nanotherapeutics she held a Postdoctoral Traineeship from 1999 to 2001 at the University of Florida. Dr. Eppler received a B.S. in Zoology and a Ph.D. in Pharmaceutical Sciences from the University of Florida. Her graduate and postdoctoral research focused on anti-oxidants and aging, as well as the neuropharmacology of cocaine and chronic ethanol exposure. Dr. Eppler has presented over 16 abstracts and published over 14 papers in the fields of pharmacodynamics and neuropharmacology.

Dennis Tomisaka joined Nanotherapeutics in 2005 as VP of Operations and Product Development. Mr. Tomisaka has extensive experience and success in leading multi-functional, technology teams in the development and successful commercialization of products in the biotechnology, implantable, and disposable medical device markets at companies including Johnson & Johnson, Baxter Healthcare and Regeneration Technologies. He earned his B.S. degree in Chemical Engineering from the University of California at Berkeley, his M.S.E. degree in Biomedical Engineering from Arizona State University, and his MBA. from The Ohio State University. He has four issued U.S. patents and has had membership and certification training in the Project Management Institute (PMI) and the Product Development Management Association (PDMA).

Dr. Kirk earned his M.S. at the Massachusetts Institute of Technology in polymer science and his Ph.D. at the University of Florida in Materials Science and Engineering, particularly in drug delivery and bio-erodible devices. Most recently he has been consulting with a variety of biomedical companies on materials selection and process development. Prior to joining Nanotherapeutics he held the position of Research Manager at Regeneration Technologies, Inc. from 2001 to 2003 and Scientist positions at Vistakon and Genzyme.  He joined Nanotherapeutics in 2004 as Director of the Manufacturing Department and oversees the newly FDA-approved bone graft product, OrigenTM DBM with Bioactive Glass Bone Graft.  Dr. Kirk has presented over 30 abstracts and been involved in 6 patents in the fields of biomedical materials and polymers.

Dennis Kristof joined Nanotherapeutics as Controller in 2006 after serving as the Controller of Oragenics, Inc. for the prior two years. His 20 years of experience includes the development and implementation of management information systems, asset liability management, investment management, and corporate and cost accounting. Mr. Kristof earned a BA in Finance and an MBA with a dual concentration in Finance and MIS from the University of South Florida. Dennis serves as Vice President of the Florida Association of Bioscience Financial Officers. He is a Certified Management Accountant and a member of the Institute of Management Accountants.

Dr. John Abernethy is the Medical Director for Nanotherapeutics. He is currently President of AMK Research, Inc. and holds a Clinical Assistant Professor position at the University of Florida. Dr. Abernethy has had experience with all aspects of Phase I through Phase IV clinical protocols and has been involved in over 30 trials over the last 10 years .

Dr. Abernethy graduated from University of Miami and received his M.D. from the University of Florida. His graduate training was at Shands Hospital in Gainesville, Florida where he was Chief Resident in his final year of Residency. He is Board Certified in Family Medicine.